Shark Tank fame Namita Thapar is expected to earn a remarkable 293-fold return on her initial investment through Emcure Pharmaceuticals IPO, as outlined in the company’s red herring prospectus. The IPO will open from July 3-5.
With the price band for Emcure Pharmaceuticals set between Rs 960 and Rs 1008 per share, Thapar may get an impressive return at the upper end of the band. She currently holds 6,339,800 shares, equating to a 3.5 percent stake in the company. Her weighted average acquisition cost per share is Rs 3.44, making her total investment approximately Rs 2.18 crore. In the offer-for-sale (OFS), Thapar will offload 1,268,600 shares.
Additionally, another key promoter, Satish Ramanlal Mehta, who holds 75,816,748 equity shares (a 41.85 percent stake in the company), will also participate in the OFS by selling up to 4,20,000 shares. At the upper end of the price band, Mehta will see a 52-fold return on his initial investment.
Meanwhile, BC Investments IV is projected to achieve a profit of 3.63 times its original investment.